ACEPODIA BIOTECHNOLOGIES, LIMITED
Update：2025/12/24
Industries
Main Industry
Health Care
Main Product/Service
1. ACC (Antibody-Cell Conjugation) technology
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
Founded Year
2017
Unified Business No.
66616512
Status
Active
Number of Employees
10
Total Paid-in
Capital
3,500,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemis
